ARYA IV (NASDAQ:ARYD) has agreed to mutually terminate its combination with the gene therapy division of biotech firm Amicus (NASDAQ:FOLD).
The news came not from ARYA IV’s end but as a part of Amicus’ quarterly updates and it primarily blamed “unfavorable market conditions affecting IPOs, follow-on financings and SPACs”. Those conditions are real and appear poised to get worse with the latest news out of Eastern Europe, but are also accompanied by news that Amicus’ CEO and COO will both also be moving on.
Whether these departures are a cause or effect of the deal’s fate are purely speculative, but it is possible that there is more than market concerns behind the decision. Nonetheless, neither side will pay breakup fees and ARYA IV has until March 2, 2023 to complete a transaction, which is plenty of time assuming the market is forgiving.
The price performance of biotech de-SPACs had been slipping as seen in SPACInsider’s Full Year 2021 Report, and Amicus itself is down about 31% since the start of the year. More than anything, it could be a sign that we see pressure on more deals struck in better times. Both sides have an easier “out” in blaming market conditions now that one more force majeure has been added to the mix.
The parties originally announced their $242 million combination in September. Headwinds aside, the ARYA team has produced the 9th-best returns (as of today) among serial SPAC teams with an average de-SPAC share price of $11.74, largely thanks to its combination with Cerevel Therapeutics (NASDAQ:CERE), which last closed at $23.50.
At the SPAC of Dawn This action-packed week in SPACs comes to an end with three more SPACs launching their IPOs, bringing it to nine on the week. And, the crypto strategy that SPACInsider noticed becoming increasingly popular among de-SPACs earlier this year has continued to gain steam. This week, edtech firm Classover (NASDAQ:KIDZ), fresh...
Cartesian Growth Corporation III (NASDAQ:CGCT) announced the pricing of its upsized $240 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “CGCT”, Friday, May 2, 2025. The new SPAC intends to combine with a closely held private company ready to make the jump to being a market-leading transnational...
Cantor Equity Partners II, Inc. (NASDAQ:CEPT) announced the pricing of its upsized $240 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “CEPT”, Friday, May 2, 2025. The new SPAC intends to combine with a target in the financial services, healthcare, real estate services, technology, or software industries....
Gores Holdings X Inc. (NASDAQ:GTENU) announced the pricing of its upsized $312 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTENU”, Friday, May 2, 2025. The new SPAC aims to combine with a target company in the industrials, technology, healthcare, or consumer sectors. Gores X’s management team...
Wen Acquisition Corp. (NASDAQ:WTENNU) has filed for a $261 million SPAC to hunt for a crypto or financial services target with a team staffed by former advisors to the FinTech SPAC series. The new SPAC is not overfunded and will have a 1/2 warrant in each unit with 24 months to initially complete a business...